NCT07450027 LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis
| NCT ID | NCT07450027 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Elazığ Mental Health and Diseases Hospital |
| Condition | Methamphetamine Use Disorder |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2026-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2025-09-01 with a primary completion date of 2026-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This cross-sectional observational case-control study aimed to examined serum levels of leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) and olfactomedin-4 (OLFM4) levels in methamphetamine use disorder (MUD), methamphetamine-induced psychotic disorder (MP), and healthy control (HC) groups. The study also aimed to assessed systemic inflammation using the Aggregate Index of Systemic Inflammation (AISI) and examined associations between biomarkers and clinical symptom severity, including Insight Assessment Scale (IAS) and Positive and Negative Syndrome Scale (PANSS) scores.
Eligibility Criteria
1. For Methamphetamine Use Disorder (MUD) Group: \*Inclusion Criteria: * Diagnosis of MUD according to DSM-5-TR * Medication-free for at least one month prior to admission * Age ≥ 18 years and \<65 years * Provided informed consent For Methamphetamine Use Disorder (MUD) Group: \*Exclusion Criteria: • Hypertension * Diabetes mellitus * Chronic kidney disease * Rheumatoid arthritis * Systemic lupus erythematosus * Cardiac illness * Severe neurological disorders * Immunological or systemic illness * Primary psychiatric disorders other than MUD * Alcohol use disorder 2. For Methamphetamine-Induced Psychotic Disorder (MP) Group: \*Inclusion Criteria: * Diagnosis of MP according to DSM-5-TR * Medication-free for at least one month prior to admission * Age ≥ 18 years and \<65 years * Provided informed consent For Methamphetamine-Induced Psychotic Disorder (MP) Group: \*Exclusion Criteria: * Hypertension * Diabetes mellitus * Chronic kidney disease * Rheumatoid arthritis * Systemic lupus erythematosus * Cardiac illness * Severe neurological disorders * Immunological or systemic illness * Primary psychiatric disorders other than MP * Alcohol use disorder 3. For Healthy Control Group: \*Inclusion Criteria: * No psychiatric diagnosis * No systemic or immunological illness * Medication-free for at least one month * Age ≥ 18 years and \<65 years * Provided informed consent For Healthy Control Group: \*Exclusion Criteria: • Hypertension * Diabetes mellitus * Chronic kidney disease * Rheumatoid arthritis * Systemic lupus erythematosus * Cardiac illness * Severe neurological disorders * Immunological or systemic illness * Primary psychiatric disorders other than schizophrenia * Alcohol/drug/substance use
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07450027 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 49 Years, studying Methamphetamine Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07450027 currently recruiting?
Yes, NCT07450027 is actively recruiting participants. Contact the research team at mhorum@hotmail.com for enrollment information.
Where is the NCT07450027 trial being conducted?
This trial is being conducted at Elâzığ, Turkey (Türkiye).
Who is sponsoring the NCT07450027 clinical trial?
NCT07450027 is sponsored by Elazığ Mental Health and Diseases Hospital. The trial plans to enroll 120 participants.